BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Science in Boston - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Science in Boston
X-ORIGINAL-URL:https://scienceinboston.com
X-WR-CALDESC:Events for Science in Boston
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Vancouver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20220313T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20221106T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20230312T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20231105T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220314T190000
DTEND;TZID=America/Toronto:20220314T200000
DTSTAMP:20260427T180428
CREATED:20220214T171620Z
LAST-MODIFIED:20220214T171620Z
UID:18827-1647284400-1647288000@scienceinboston.com
SUMMARY:The Code Breaker: A Conversation with Jennifer Doudna
DESCRIPTION:Join Ruth Lehmann\, Director\, Whitehead Institute as she speaks with Jennifer Doudna\, University of California\, Berkeley professor and Nobel Laureate\, about her role in the development of CRISPR-Cas9. They will discuss the potential applications of this world-changing genetic technology\, the societal and ethical implications of gene editing as well as current research projects\, collaborations\, and new advances in biology.
URL:https://scienceinboston.com/event/the-code-breaker-a-conversation-with-jennifer-doudna/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220314T190000
DTEND;TZID=America/Toronto:20220314T200000
DTSTAMP:20260427T180428
CREATED:20220214T171620Z
LAST-MODIFIED:20220214T171620Z
UID:27808-1647284400-1647288000@scienceinboston.com
SUMMARY:The Code Breaker: A Conversation with Jennifer Doudna
DESCRIPTION:Join Ruth Lehmann\, Director\, Whitehead Institute as she speaks with Jennifer Doudna\, University of California\, Berkeley professor and Nobel Laureate\, about her role in the development of CRISPR-Cas9. They will discuss the potential applications of this world-changing genetic technology\, the societal and ethical implications of gene editing as well as current research projects\, collaborations\, and new advances in biology.
URL:https://scienceinboston.com/event/the-code-breaker-a-conversation-with-jennifer-doudna-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20220310T173000
DTEND;TZID=America/Vancouver:20220310T183000
DTSTAMP:20260427T180428
CREATED:20220218T185511Z
LAST-MODIFIED:20220221T185420Z
UID:18865-1646933400-1646937000@scienceinboston.com
SUMMARY:2022 Koch Institute Image Awards
DESCRIPTION:As we celebrate the opening of the 12th annual Image Awards exhibition\, the Koch Institute is proud to shine a light on the continued biomedical research happening at MIT. Join us on Zoom for live-streamed lightning talks by the  scientists and engineers behind this year’s award-winning visuals.
URL:https://scienceinboston.com/event/2022-image-awards/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20220310T173000
DTEND;TZID=America/Vancouver:20220310T183000
DTSTAMP:20260427T180428
CREATED:20220218T185511Z
LAST-MODIFIED:20220218T185511Z
UID:27810-1646933400-1646937000@scienceinboston.com
SUMMARY:2022 Koch Institute Image Awards
DESCRIPTION:As we celebrate the opening of the 12th annual Image Awards exhibition\, the Koch Institute is proud to shine a light on the continued biomedical research happening at MIT. Join us on Zoom for live-streamed lightning talks by the  scientists and engineers behind this year’s award-winning visuals.
URL:https://scienceinboston.com/event/2022-image-awards-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20220310T090000
DTEND;TZID=America/Vancouver:20220310T101500
DTSTAMP:20260427T180428
CREATED:20220307T190200Z
LAST-MODIFIED:20220307T190200Z
UID:19122-1646902800-1646907300@scienceinboston.com
SUMMARY:Harvard Startup Stories: Beacon Bio
DESCRIPTION:Hop on Zoom for this lunchtime talk featuring the founder of Beacon Bio\, a biomedical device startup which launched to commercialize innovations developed at Harvard SEAS\, Harvard’s Wyss Institute\, and Mass Eye & Ear. \nFeatured speaker: \nNicole Black\, PhD ’20\, founder and CEO of Beacon Bio and now Vice President of Biomaterials and Innovation at Desktop Health. \nDr. Black founded Beacon Bio to commercialize a biomimetic hearing-restoration technology developed at Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS)\, the Wyss Institute for Biologically Inspired Engineering at Harvard University\, and Mass Eye & Ear. Dr. Black had advanced this research as a SEAS doctoral student in the lab of Prof. Jennifer Lewis\, and the work was advanced toward commercialization as an Institute Project at the Wyss. The core technology\, called the PhonoGraft device\, is a 3D-printed\, biocompatible graft that could be implanted to repair a damaged eardrum. If its clinical development is successful\, the PhonoGraft technology could mitigate the pain\, drainage\, and hearing loss associated with ear drum perforations that affect millions of individuals worldwide. Shortly after its launch\, Beacon Bio was acquired by California-based Desktop Health\, a healthcare business within Desktop Metal Inc. that focuses on new 3D printing and biofabrication solutions for personalized medicine. Dr. Black\, who was CEO of Beacon Bio and is a Wyss Lumineer\, continues to lead the platform as Vice President of Biomaterials and Innovation at Desktop Health. Read more about the launch and acquisition of Beacon Bio. \nShe will be joined by Chris Petty\, PhD\, Director of Business Development in Harvard Office of Technology Development.
URL:https://scienceinboston.com/event/harvard-startup-stories-beacon-bio/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20220310T090000
DTEND;TZID=America/Vancouver:20220310T101500
DTSTAMP:20260427T180428
CREATED:20220307T190200Z
LAST-MODIFIED:20220307T190200Z
UID:27815-1646902800-1646907300@scienceinboston.com
SUMMARY:Harvard Startup Stories: Beacon Bio
DESCRIPTION:Hop on Zoom for this lunchtime talk featuring the founder of Beacon Bio\, a biomedical device startup which launched to commercialize innovations developed at Harvard SEAS\, Harvard’s Wyss Institute\, and Mass Eye & Ear. \nFeatured speaker: \nNicole Black\, PhD ’20\, founder and CEO of Beacon Bio and now Vice President of Biomaterials and Innovation at Desktop Health. \nDr. Black founded Beacon Bio to commercialize a biomimetic hearing-restoration technology developed at Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS)\, the Wyss Institute for Biologically Inspired Engineering at Harvard University\, and Mass Eye & Ear. Dr. Black had advanced this research as a SEAS doctoral student in the lab of Prof. Jennifer Lewis\, and the work was advanced toward commercialization as an Institute Project at the Wyss. The core technology\, called the PhonoGraft device\, is a 3D-printed\, biocompatible graft that could be implanted to repair a damaged eardrum. If its clinical development is successful\, the PhonoGraft technology could mitigate the pain\, drainage\, and hearing loss associated with ear drum perforations that affect millions of individuals worldwide. Shortly after its launch\, Beacon Bio was acquired by California-based Desktop Health\, a healthcare business within Desktop Metal Inc. that focuses on new 3D printing and biofabrication solutions for personalized medicine. Dr. Black\, who was CEO of Beacon Bio and is a Wyss Lumineer\, continues to lead the platform as Vice President of Biomaterials and Innovation at Desktop Health. Read more about the launch and acquisition of Beacon Bio. \nShe will be joined by Chris Petty\, PhD\, Director of Business Development in Harvard Office of Technology Development.
URL:https://scienceinboston.com/event/harvard-startup-stories-beacon-bio-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220308T160000
DTEND;TZID=America/Toronto:20220308T170000
DTSTAMP:20260427T180428
CREATED:20220307T185814Z
LAST-MODIFIED:20220307T190525Z
UID:19119-1646755200-1646758800@scienceinboston.com
SUMMARY:Biology Colloquium Series: Seemay Chou\, UCSF
DESCRIPTION:Speaker: Seemay Chou\, UCSF \nHost: Rebecca Lamason \nTitle: “Friend or foe? Ticks and their many microbes.” \nThe Biology Colloquium is a weekly seminar held throughout the academic year — featuring distinguished speakers in many areas of the biological sciences from universities and institutions worldwide. More information on speakers\, their affiliations\, and titles of their talks will be added as available. Unless otherwise stated\, the Colloquium will be held via Zoom at 4:00PM ET on Tuesdays. Contact Margaret Cabral with questions.
URL:https://scienceinboston.com/event/biology-colloquium-series-seemay-chou-ucsf/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220308T160000
DTEND;TZID=America/Toronto:20220308T170000
DTSTAMP:20260427T180428
CREATED:20220307T185814Z
LAST-MODIFIED:20220307T185814Z
UID:27814-1646755200-1646758800@scienceinboston.com
SUMMARY:Biology Colloquium Series: Seemay Chou\, UCSF
DESCRIPTION:Speaker: Seemay Chou\, UCSF \nHost: Rebecca Lamason \nTitle: “Friend or foe? Ticks and their many microbes.” \nThe Biology Colloquium is a weekly seminar held throughout the academic year — featuring distinguished speakers in many areas of the biological sciences from universities and institutions worldwide. More information on speakers\, their affiliations\, and titles of their talks will be added as available. Unless otherwise stated\, the Colloquium will be held via Zoom at 4:00PM ET on Tuesdays. Contact Margaret Cabral with questions.
URL:https://scienceinboston.com/event/biology-colloquium-series-seemay-chou-ucsf-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220308T120000
DTEND;TZID=America/Toronto:20220308T133000
DTSTAMP:20260427T180428
CREATED:20220217T232716Z
LAST-MODIFIED:20220228T205139Z
UID:18862-1646740800-1646746200@scienceinboston.com
SUMMARY:PhD Career Prototype Series - Careers in the Pharmaceutical Industry
DESCRIPTION:This Career Prototype Series engages industry professionals with PhDs to share their career trajectories and facilitate a hands-on activity enabling participants to try solving a typical problem they might face within industry. \nSpeaker: Ari Salinger\, Ph.D. Proteomics Senior Scientist Bristol Myers Squibb \nYou can learn more about Ari’s career path by checking out his LinkedIn profile: https://www.linkedin.com/in/ari-salinger-17540b125/
URL:https://scienceinboston.com/event/phd-career-prototype-series-careers-in-the-pharmaceutical-industry/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220308T120000
DTEND;TZID=America/Toronto:20220308T133000
DTSTAMP:20260427T180428
CREATED:20220217T232716Z
LAST-MODIFIED:20220217T232716Z
UID:27809-1646740800-1646746200@scienceinboston.com
SUMMARY:PhD Career Prototype Series - Careers in the Pharmaceutical Industry
DESCRIPTION:This Career Prototype Series engages industry professionals with PhDs to share their career trajectories and facilitate a hands-on activity enabling participants to try solving a typical problem they might face within industry. \nSpeaker: Ari Salinger\, Ph.D. Proteomics Senior Scientist Bristol Myers Squibb \nYou can learn more about Ari’s career path by checking out his LinkedIn profile: https://www.linkedin.com/in/ari-salinger-17540b125/
URL:https://scienceinboston.com/event/phd-career-prototype-series-careers-in-the-pharmaceutical-industry-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220308T110000
DTEND;TZID=America/Toronto:20220308T114500
DTSTAMP:20260427T180428
CREATED:20220307T185707Z
LAST-MODIFIED:20220307T185707Z
UID:19116-1646737200-1646739900@scienceinboston.com
SUMMARY:Nano Explorations: Implantable Soft Robotic Platform for Enhanced Drug Delivery
DESCRIPTION:Debkalpa Goswami\, Postdoctoral Associate\nInstitute for Medical Engineering & Science (IMES) \nFibrous capsule formation\, and its effect on molecular transport\, can be detrimental to the long-term efficacy of implantable drug delivery devices\, especially when precise spatial and temporal control is necessary for safe and effective therapy delivery. In this talk\, Dr. Goswami will describe an implantable platform which can overcome the diffusional barrier of the fibrous capsule to achieve enhanced transport of small and macromolecular therapy using multiple synergistic soft robotic strategies. \nUsing this platform\, small amplitude dynamic actuation (preconditioning) applied to subcutaneous tissue in mice leads to a downstream functional effect: enhanced passive transport of insulin (a model macromolecule) and glycemic control. Furthermore\, rapid actuation of the platform at the time of drug delivery can accelerate transport via convective fluid flow and overcome diffusional limitations caused by the fibrous capsule. \nThis soft actuatable platform has potential clinical utility for mediating and overcoming the host fibrotic response\, leading to enhanced delivery of drug therapy for a variety of indications\, such as diabetes.
URL:https://scienceinboston.com/event/nano-explorations-implantable-soft-robotic-platform-for-enhanced-drug-delivery/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220308T110000
DTEND;TZID=America/Toronto:20220308T114500
DTSTAMP:20260427T180428
CREATED:20220307T185707Z
LAST-MODIFIED:20220307T185707Z
UID:27813-1646737200-1646739900@scienceinboston.com
SUMMARY:Nano Explorations: Implantable Soft Robotic Platform for Enhanced Drug Delivery
DESCRIPTION:Debkalpa Goswami\, Postdoctoral Associate\nInstitute for Medical Engineering & Science (IMES) \nFibrous capsule formation\, and its effect on molecular transport\, can be detrimental to the long-term efficacy of implantable drug delivery devices\, especially when precise spatial and temporal control is necessary for safe and effective therapy delivery. In this talk\, Dr. Goswami will describe an implantable platform which can overcome the diffusional barrier of the fibrous capsule to achieve enhanced transport of small and macromolecular therapy using multiple synergistic soft robotic strategies. \nUsing this platform\, small amplitude dynamic actuation (preconditioning) applied to subcutaneous tissue in mice leads to a downstream functional effect: enhanced passive transport of insulin (a model macromolecule) and glycemic control. Furthermore\, rapid actuation of the platform at the time of drug delivery can accelerate transport via convective fluid flow and overcome diffusional limitations caused by the fibrous capsule. \nThis soft actuatable platform has potential clinical utility for mediating and overcoming the host fibrotic response\, leading to enhanced delivery of drug therapy for a variety of indications\, such as diabetes.
URL:https://scienceinboston.com/event/nano-explorations-implantable-soft-robotic-platform-for-enhanced-drug-delivery-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220302T160000
DTEND;TZID=America/Toronto:20220302T170000
DTSTAMP:20260427T180428
CREATED:20211202T221137Z
LAST-MODIFIED:20220218T184813Z
UID:17761-1646236800-1646240400@scienceinboston.com
SUMMARY:SeXX and Immunity
DESCRIPTION:The X chromosome does more than determine sex! When we treat biological sex (XX versus XY chromosomes) as a variable in immunity and diseases\, it can lead to a new understanding of the underpinnings of disease. The COVID-19 pandemic helped amplify awareness about sex-specific differences in immunity against infection\, however\, we still have a lot to learn. Sex differences in disease outcomes are not limited to infectious diseases – they are observed in outcomes of autoimmune diseases and cancers\, and even in response to vaccination. \nOn January 19\, 2022\, MIT will kick off a new series of discussions and seminars called “SeXX and Immunity.” These sessions will explore our understanding of sex differences and sex dimorphism in relation to immune responses and how presentations of infectious diseases differ based on biology. \nOur first session will feature Dr. Sabra Klein of Johns Hopkins University\, for a talk titled “SeXX matters for viral infection and vaccination.”
URL:https://scienceinboston.com/event/sexx-and-immunity/
LOCATION:MIT\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220302T160000
DTEND;TZID=America/Toronto:20220302T170000
DTSTAMP:20260427T180428
CREATED:20211202T221137Z
LAST-MODIFIED:20211202T221137Z
UID:27778-1646236800-1646240400@scienceinboston.com
SUMMARY:SeXX and Immunity
DESCRIPTION:The X chromosome does more than determine sex! When we treat biological sex (XX versus XY chromosomes) as a variable in immunity and diseases\, it can lead to a new understanding of the underpinnings of disease. The COVID-19 pandemic helped amplify awareness about sex-specific differences in immunity against infection\, however\, we still have a lot to learn. Sex differences in disease outcomes are not limited to infectious diseases – they are observed in outcomes of autoimmune diseases and cancers\, and even in response to vaccination. \nOn January 19\, 2022\, MIT will kick off a new series of discussions and seminars called “SeXX and Immunity.” These sessions will explore our understanding of sex differences and sex dimorphism in relation to immune responses and how presentations of infectious diseases differ based on biology. \nOur first session will feature Dr. Sabra Klein of Johns Hopkins University\, for a talk titled “SeXX matters for viral infection and vaccination.”
URL:https://scienceinboston.com/event/sexx-and-immunity-2/
LOCATION:MIT\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220301T130000
DTEND;TZID=America/Toronto:20220301T140000
DTSTAMP:20260427T180428
CREATED:20220221T190859Z
LAST-MODIFIED:20220221T190859Z
UID:18922-1646139600-1646143200@scienceinboston.com
SUMMARY:Frontiers in Biostatistics: Considerations for Extracting Real-World Evidence from Real-World Data
DESCRIPTION:Opportunities to use real-world data (RWD)\, including electronic health records (EHR) and medical claims data\, have exploded over the past decade. The Covid-19 pandemic has provided a particularly dramatic illustration of the potential value of RWD for advancing medical research as well as the high-risk of bias inherent to many such studies. Using data sources that were not collected for research purposes comes at a cost\, and naïve use of these data without considering their complexity and imperfect quality can lead to biased inference. While RWD offer the opportunity to generate timely evidence grounded in real-world populations and clinical practice\, issues of information bias and confounding create serious threats to the validity of these studies. The statistician is faced with a quandary: how to effectively utilize RWD to advance research without compromising best practices for principled data analysis. In this talk I will use examples from my research on methods for the analysis of EHR derived-data to illustrate how an understanding of the EHR data generating mechanism can inform selection of appropriate study questions and development and application of statistical methods that minimize the risk of bias. The overarching goal of this presentation is to raise awareness of challenges associated with the analysis of RWD and demonstrate that valid evidence generation can be grounded in an understanding of the scientific context and data generating process. \nDr. Rebecca Hubbard’s research focuses on the development and application of methods to improve analyses using real world data sources including electronic health records (EHR) and claims data. The data science era demands novel analytic methods to transform the wealth of data created as a byproduct of our digital interactions into valid and generalizable knowledge. Dr. Hubbard’s research emphasizes statistical methods designed to meet this challenge by addressing the messiness and complexity of real world data including informative observation schemes\, phenotyping error\, and error and missingness in confounders. Her methods have been applied to support the advancement of a broad range of research areas through use of EHR and claims data including health services research\, cancer epidemiology\, aging and dementia\, and pharmacoepidemiology.
URL:https://scienceinboston.com/event/frontiers-in-biostatistics-considerations-for-extracting-real-world-evidence-from-real-world-data/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220301T130000
DTEND;TZID=America/Toronto:20220301T140000
DTSTAMP:20260427T180428
CREATED:20220221T190859Z
LAST-MODIFIED:20220221T190859Z
UID:27811-1646139600-1646143200@scienceinboston.com
SUMMARY:Frontiers in Biostatistics: Considerations for Extracting Real-World Evidence from Real-World Data
DESCRIPTION:Opportunities to use real-world data (RWD)\, including electronic health records (EHR) and medical claims data\, have exploded over the past decade. The Covid-19 pandemic has provided a particularly dramatic illustration of the potential value of RWD for advancing medical research as well as the high-risk of bias inherent to many such studies. Using data sources that were not collected for research purposes comes at a cost\, and naïve use of these data without considering their complexity and imperfect quality can lead to biased inference. While RWD offer the opportunity to generate timely evidence grounded in real-world populations and clinical practice\, issues of information bias and confounding create serious threats to the validity of these studies. The statistician is faced with a quandary: how to effectively utilize RWD to advance research without compromising best practices for principled data analysis. In this talk I will use examples from my research on methods for the analysis of EHR derived-data to illustrate how an understanding of the EHR data generating mechanism can inform selection of appropriate study questions and development and application of statistical methods that minimize the risk of bias. The overarching goal of this presentation is to raise awareness of challenges associated with the analysis of RWD and demonstrate that valid evidence generation can be grounded in an understanding of the scientific context and data generating process. \nDr. Rebecca Hubbard’s research focuses on the development and application of methods to improve analyses using real world data sources including electronic health records (EHR) and claims data. The data science era demands novel analytic methods to transform the wealth of data created as a byproduct of our digital interactions into valid and generalizable knowledge. Dr. Hubbard’s research emphasizes statistical methods designed to meet this challenge by addressing the messiness and complexity of real world data including informative observation schemes\, phenotyping error\, and error and missingness in confounders. Her methods have been applied to support the advancement of a broad range of research areas through use of EHR and claims data including health services research\, cancer epidemiology\, aging and dementia\, and pharmacoepidemiology.
URL:https://scienceinboston.com/event/frontiers-in-biostatistics-considerations-for-extracting-real-world-evidence-from-real-world-data-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20220228T100000
DTEND;TZID=America/Vancouver:20220228T123000
DTSTAMP:20260427T180428
CREATED:20211220T022053Z
LAST-MODIFIED:20211220T022053Z
UID:18034-1646042400-1646051400@scienceinboston.com
SUMMARY:2022 Rare Disease Day
DESCRIPTION:MassBio’s Rare Disease Day recognizes the research being done in Massachusetts to treat and cure rare disease. The last day of February has been designated as Rare Disease Day in Massachusetts to call attention to the public health issues associated with rare diseases\, which affect nearly 30 million Americans and countless others around the world. \nThis year’s program will focus on how we can better address health inequity and racial disparities among the rare disease community. Attendees will hear an inspiring Possible Talk\, an insightful panel of industry\, physicians\, patients/caregivers\, and advocates\, and a closing patient keynote. Ample networking time will be provided (virtually!). \nAlone we are rare\, together we are strong. \nTo inquire about sponsorship opportunities\, contact Laura Rudberg. \nNOTE: MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations\, such as captioning.
URL:https://scienceinboston.com/event/2022-rare-disease-day/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20220228T100000
DTEND;TZID=America/Vancouver:20220228T123000
DTSTAMP:20260427T180428
CREATED:20211220T022053Z
LAST-MODIFIED:20211220T022053Z
UID:27790-1646042400-1646051400@scienceinboston.com
SUMMARY:2022 Rare Disease Day
DESCRIPTION:MassBio’s Rare Disease Day recognizes the research being done in Massachusetts to treat and cure rare disease. The last day of February has been designated as Rare Disease Day in Massachusetts to call attention to the public health issues associated with rare diseases\, which affect nearly 30 million Americans and countless others around the world. \nThis year’s program will focus on how we can better address health inequity and racial disparities among the rare disease community. Attendees will hear an inspiring Possible Talk\, an insightful panel of industry\, physicians\, patients/caregivers\, and advocates\, and a closing patient keynote. Ample networking time will be provided (virtually!). \nAlone we are rare\, together we are strong. \nTo inquire about sponsorship opportunities\, contact Laura Rudberg. \nNOTE: MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations\, such as captioning.
URL:https://scienceinboston.com/event/2022-rare-disease-day-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220218T130000
DTEND;TZID=America/Toronto:20220218T140000
DTSTAMP:20260427T180428
CREATED:20220214T171419Z
LAST-MODIFIED:20220214T171419Z
UID:18824-1645189200-1645192800@scienceinboston.com
SUMMARY:Faculty Career Panel - Faculty Roles at Different US Institution Types
DESCRIPTION:The higher education landscape in the United States includes many different types of institutions: research-intensive\, teaching-intensive\, large\, small\, private\, public and many variations in between. Join a panel of faculty from different institution types to learn more about these various options\, the balance of teaching\, research\, and service\, and advice for the job search. After a few starter questions from the moderator\, we will take questions from the audience.
URL:https://scienceinboston.com/event/faculty-career-panel-faculty-roles-at-different-us-institution-types/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220218T130000
DTEND;TZID=America/Toronto:20220218T140000
DTSTAMP:20260427T180428
CREATED:20220214T171419Z
LAST-MODIFIED:20220214T171419Z
UID:27807-1645189200-1645192800@scienceinboston.com
SUMMARY:Faculty Career Panel - Faculty Roles at Different US Institution Types
DESCRIPTION:The higher education landscape in the United States includes many different types of institutions: research-intensive\, teaching-intensive\, large\, small\, private\, public and many variations in between. Join a panel of faculty from different institution types to learn more about these various options\, the balance of teaching\, research\, and service\, and advice for the job search. After a few starter questions from the moderator\, we will take questions from the audience.
URL:https://scienceinboston.com/event/faculty-career-panel-faculty-roles-at-different-us-institution-types-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220216T130000
DTEND;TZID=America/Toronto:20220216T140000
DTSTAMP:20260427T180428
CREATED:20220202T165231Z
LAST-MODIFIED:20220214T184103Z
UID:18626-1645016400-1645020000@scienceinboston.com
SUMMARY:DEI Seminar 2/16: Recognizing and Responding to Racism: Lessons for Health and Medicine
DESCRIPTION:The Institute’s Diversity\, Equity & Inclusion (DE&I) Seminar Series continues with Dr. Matthew Clair\, Assistant Professor in the Department of Sociology and (by courtesy) the Law School at  Stanford University.Dr. Clair’s talk\, titled “Recognizing and Responding to Racism: Lessons for Health and Medicine”\, will explore social inequities in medicine. \nThe Seminar will be held virtually on Wednesday February 16th from 1 – 2 PM (Zoom details below). Dr. Clair’s research to date has focused on inequality and violence in the criminal legal system\, legal institutions\, and the legal profession. He is the author of the award-winning book Privilege and Punishment: How Race and Class Matter in Criminal Court (Princeton University Press\, 2020). He has also published in several academic and popular outlets\, including Criminology\, Social Science & Medicine\, Social Forces\, The Guardian\, and The Nation. Dr. Clair has received funding from the National Science Foundation and awards from the American Sociological Association\, the American Society of Criminology\, the Law & Society Association\, and the Society for the Study of Social Problems. Prior to joining Stanford\, Dr. Clair was a postdoctoral fellow at the University of Pennsylvania Law School’s Quattrone Center. He holds an A.B. in Government from Harvard College and an A.M. and Ph.D. in Sociology from Harvard University.\nZoom Link  \nPasscode 605099
URL:https://scienceinboston.com/event/dei-seminar-2-16-recognizing-and-responding-to-racism-lessons-for-health-and-medicine/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220216T130000
DTEND;TZID=America/Toronto:20220216T140000
DTSTAMP:20260427T180428
CREATED:20220202T165231Z
LAST-MODIFIED:20220202T165231Z
UID:27803-1645016400-1645020000@scienceinboston.com
SUMMARY:DEI Seminar 2/16: Recognizing and Responding to Racism: Lessons for Health and Medicine
DESCRIPTION:The Institute’s Diversity\, Equity & Inclusion (DE&I) Seminar Series continues with Dr. Matthew Clair\, Assistant Professor in the Department of Sociology and (by courtesy) the Law School at  Stanford University.Dr. Clair’s talk\, titled “Recognizing and Responding to Racism: Lessons for Health and Medicine”\, will explore social inequities in medicine. \nThe Seminar will be held virtually on Wednesday February 16th from 1 – 2 PM (Zoom details below). Dr. Clair’s research to date has focused on inequality and violence in the criminal legal system\, legal institutions\, and the legal profession. He is the author of the award-winning book Privilege and Punishment: How Race and Class Matter in Criminal Court (Princeton University Press\, 2020). He has also published in several academic and popular outlets\, including Criminology\, Social Science & Medicine\, Social Forces\, The Guardian\, and The Nation. Dr. Clair has received funding from the National Science Foundation and awards from the American Sociological Association\, the American Society of Criminology\, the Law & Society Association\, and the Society for the Study of Social Problems. Prior to joining Stanford\, Dr. Clair was a postdoctoral fellow at the University of Pennsylvania Law School’s Quattrone Center. He holds an A.B. in Government from Harvard College and an A.M. and Ph.D. in Sociology from Harvard University.\nZoom Link  \nPasscode 605099
URL:https://scienceinboston.com/event/dei-seminar-2-16-recognizing-and-responding-to-racism-lessons-for-health-and-medicine-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220215T170000
DTEND;TZID=America/Toronto:20220215T180000
DTSTAMP:20260427T180428
CREATED:20220214T171214Z
LAST-MODIFIED:20220214T171214Z
UID:18821-1644944400-1644948000@scienceinboston.com
SUMMARY:Count Me In: How Engaging Patients Can Accelerate Cancer Research
DESCRIPTION:In the United States alone\, nearly 2 million people were diagnosed with cancer last year. Only a fraction of them\, though\, will have the opportunity to participate in research that could benefit them or others like them. Join Nikhil Wagle\, Elana Anastasio\, and Colleen Nguyen as they talk about Count Me In\, a project that engages patients everywhere in the US and Canada diagnosed with any kind of cancer\, and enables them to accelerate cancer research by sharing their samples\, their clinical information\, and their voices.
URL:https://scienceinboston.com/event/count-me-in-how-engaging-patients-can-accelerate-cancer-research/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220215T170000
DTEND;TZID=America/Toronto:20220215T180000
DTSTAMP:20260427T180428
CREATED:20220214T171214Z
LAST-MODIFIED:20220214T171214Z
UID:27806-1644944400-1644948000@scienceinboston.com
SUMMARY:Count Me In: How Engaging Patients Can Accelerate Cancer Research
DESCRIPTION:In the United States alone\, nearly 2 million people were diagnosed with cancer last year. Only a fraction of them\, though\, will have the opportunity to participate in research that could benefit them or others like them. Join Nikhil Wagle\, Elana Anastasio\, and Colleen Nguyen as they talk about Count Me In\, a project that engages patients everywhere in the US and Canada diagnosed with any kind of cancer\, and enables them to accelerate cancer research by sharing their samples\, their clinical information\, and their voices.
URL:https://scienceinboston.com/event/count-me-in-how-engaging-patients-can-accelerate-cancer-research-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220211T123000
DTEND;TZID=America/Toronto:20220211T140000
DTSTAMP:20260427T180428
CREATED:20220131T183627Z
LAST-MODIFIED:20220131T183627Z
UID:18592-1644582600-1644588000@scienceinboston.com
SUMMARY:Should Alexa Diagnose Alzheimer’s?: A Health Policy and Bioethics Consortium
DESCRIPTION:Technology is now part of our lives in ways that were not possible only 10-20 years ago. Smart devices\, like watches\, phones\, and speakers\, can gather vast amounts of information about their users\, often without the user’s knowledge or consent. As technology continues to improve\, many of these devices may also be leveraged to serve diagnostic functions. Technologies such as Amazon’s Alexa and Google’s Assistant can ambiently and continually monitor a variety of information about an individual’s location\, voice\, and movement. As this technology merges with wearables\, such as the Apple Watch or FitBit\, it may become possible to diagnose a wide range of diseases\, including Alzhiemer’s. But should it? \nTo help answer that question\, Dr. Barbara Evans and Dr. Jason Karlawish will discuss the medical\, legal\, and ethical implications of using such technology to diagnose diseases\, such as Alzhiemer’s. \nPanelists\nIntroduction: Carmel Shachar\, Executive Director\, Petrie-Flom Center \nBarbara Evans\, Professor of Law and Stephen C. O’Connell Chair\, Fredric G. Levin College of Law and Professor of Engineering\, Herbert Wertheim College of Engineering\, University of Florida \nJason Karlawish\, Professor of Medicine\, Perelman School of Medicine at the University of Pennsylvania \nModerator: David A. Simon\, Research Fellow\, Digital Home Health\, Petrie-Flom Center \nThe Health Policy and Bioethics Consortia is a monthly series that convenes two international experts from different fields or vantage points to discuss how biomedical innovation and health care delivery are affected by various ethical norms\, laws\, and regulations. \nThey are organized by the Harvard Medical School Center for Bioethics and the Program on Regulation\, Therapeutics\, and Law (PORTAL) at Brigham and Women’s Hospital\, in collaboration with the Petrie-Flom Center for Health Law Policy\, Biotechnology\, and Bioethics at Harvard Law School. Support provided by the Oswald DeN. Cammann Fund at Harvard University.
URL:https://scienceinboston.com/event/should-alexa-diagnose-alzheimers-a-health-policy-and-bioethics-consortium/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220211T123000
DTEND;TZID=America/Toronto:20220211T140000
DTSTAMP:20260427T180428
CREATED:20220131T183627Z
LAST-MODIFIED:20220131T183627Z
UID:27802-1644582600-1644588000@scienceinboston.com
SUMMARY:Should Alexa Diagnose Alzheimer’s?: A Health Policy and Bioethics Consortium
DESCRIPTION:Technology is now part of our lives in ways that were not possible only 10-20 years ago. Smart devices\, like watches\, phones\, and speakers\, can gather vast amounts of information about their users\, often without the user’s knowledge or consent. As technology continues to improve\, many of these devices may also be leveraged to serve diagnostic functions. Technologies such as Amazon’s Alexa and Google’s Assistant can ambiently and continually monitor a variety of information about an individual’s location\, voice\, and movement. As this technology merges with wearables\, such as the Apple Watch or FitBit\, it may become possible to diagnose a wide range of diseases\, including Alzhiemer’s. But should it? \nTo help answer that question\, Dr. Barbara Evans and Dr. Jason Karlawish will discuss the medical\, legal\, and ethical implications of using such technology to diagnose diseases\, such as Alzhiemer’s. \nPanelists\nIntroduction: Carmel Shachar\, Executive Director\, Petrie-Flom Center \nBarbara Evans\, Professor of Law and Stephen C. O’Connell Chair\, Fredric G. Levin College of Law and Professor of Engineering\, Herbert Wertheim College of Engineering\, University of Florida \nJason Karlawish\, Professor of Medicine\, Perelman School of Medicine at the University of Pennsylvania \nModerator: David A. Simon\, Research Fellow\, Digital Home Health\, Petrie-Flom Center \nThe Health Policy and Bioethics Consortia is a monthly series that convenes two international experts from different fields or vantage points to discuss how biomedical innovation and health care delivery are affected by various ethical norms\, laws\, and regulations. \nThey are organized by the Harvard Medical School Center for Bioethics and the Program on Regulation\, Therapeutics\, and Law (PORTAL) at Brigham and Women’s Hospital\, in collaboration with the Petrie-Flom Center for Health Law Policy\, Biotechnology\, and Bioethics at Harvard Law School. Support provided by the Oswald DeN. Cammann Fund at Harvard University.
URL:https://scienceinboston.com/event/should-alexa-diagnose-alzheimers-a-health-policy-and-bioethics-consortium-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20220210T170000
DTEND;TZID=America/Vancouver:20220210T190000
DTSTAMP:20260427T180428
CREATED:20220114T205635Z
LAST-MODIFIED:20220114T205635Z
UID:18361-1644512400-1644519600@scienceinboston.com
SUMMARY:MassBio Trivia
DESCRIPTION:Come test your wits and connect with other MassBio members at our in-person trivia event! Come as a team or as an individual to grow your network and meet other life sciences professionals in a fun casual environment. Appetizers and drinks will be served. \nFree for MassBio Members. Registration is required. \nTo inquire about sponsorship opportunities\, contact Jessica Sousa. \nIn-person attendance is available on a first-come-first-served basis\, and all additional registrants will be placed on a waitlist. All attendees for this event are required to be fully vaccinated and masks will be required in all common areas of the event space\, except while eating or drinking. MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations.
URL:https://scienceinboston.com/event/massbio-trivia/
LOCATION:MassBioHub\, 700 Technology Square\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20220210T170000
DTEND;TZID=America/Vancouver:20220210T190000
DTSTAMP:20260427T180428
CREATED:20220114T205635Z
LAST-MODIFIED:20220114T205635Z
UID:27797-1644512400-1644519600@scienceinboston.com
SUMMARY:MassBio Trivia
DESCRIPTION:Come test your wits and connect with other MassBio members at our in-person trivia event! Come as a team or as an individual to grow your network and meet other life sciences professionals in a fun casual environment. Appetizers and drinks will be served. \nFree for MassBio Members. Registration is required. \nTo inquire about sponsorship opportunities\, contact Jessica Sousa. \nIn-person attendance is available on a first-come-first-served basis\, and all additional registrants will be placed on a waitlist. All attendees for this event are required to be fully vaccinated and masks will be required in all common areas of the event space\, except while eating or drinking. MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations.
URL:https://scienceinboston.com/event/massbio-trivia-2/
LOCATION:MassBioHub\, 700 Technology Square\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220208T153000
DTEND;TZID=America/Toronto:20220208T170000
DTSTAMP:20260427T180428
CREATED:20220114T205434Z
LAST-MODIFIED:20220114T205434Z
UID:18356-1644334200-1644339600@scienceinboston.com
SUMMARY:Astellas Pharma Day
DESCRIPTION:Accelerate your biotech company\, startup\, or university’s innovation portfolio at our Astellas 2022 Pharma Day on February 8. \nMassBio’s Pharma Days® are unparalleled opportunities for emerging innovators to learn from and connect with world-leading biopharmaceutical companies. \nDiscover on February 8 | Join Astellas’ open information session on February 8 for the latest insights on its R&D strategy\, target therapeutic areas\, and partnering capabilities. This session will be followed by a networking reception. This session will feature: \n\nHide Goto\, Ph.D.\, President\, Astellas Institute for Regenerative Medicine\nMichael Luther\, Ph.D.\, MBA\, Head of Early Stage Partnering\, Astellas\nMichael Patane\, Ph.D.\, President\, Mitobridge\nMat Pletcher\, Ph.D.\, Division Head of Gene Therapy Research & Technical Operations\, Astellas Gene Therapies\nJoanna Stanicka\, Ph.D.\, CEO and Founder\, Axonis\n\nPlease note: MassBio is taking all appropriate precautions while also closely monitoring the latest public health guidance on COVID-19. Accordingly\, all attendees for this event are required to be fully vaccinated. \nConnect on February 8 | Innovators with small molecule\, gene therapy\, mRNA\, or cell therapy candidates or technology in the therapeutic areas listed below who are actively looking for licensing opportunities are encouraged to apply for a one-on-one meeting with Astellas representatives. Astellas’ target therapeutic areas are: \n•    Oncology\n•    Immuno-Science\n•    Mitochondria Biology\n•    Regeneration/Reprogramming\nApplications for one-on-one meetings can be found here\, and must be submitted by January 7\, 2022 at 12:00AM (midnight) ET. \nProtection of intellectual property rights (ex. patents\, trademarks\, copyright\, trade secrets\, etc.) of your concept is your responsibility and your responsibility alone. Information you include in your application will be shared with State of Possible partners. Please note that these partners did NOT sign Non-Disclosure Agreements (NDAs). Therefore\, you should not include any information in your application that you feel could be harmful to your company should that information be disclosed. \nPlease note that this will be a hybrid event\, with a limited number of in-person attendees. In-person attendance is available on a first-come-first-serve basis\, and all additional registrants will be placed on a waitlist. All attendees for this event are required to be fully vaccinated and masks will be required in all common areas of the event space\, except while eating or drinking.  
URL:https://scienceinboston.com/event/astellas-pharma-day/
LOCATION:MassBioHub & Online\, 700 Technology Square\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220208T153000
DTEND;TZID=America/Toronto:20220208T170000
DTSTAMP:20260427T180428
CREATED:20220114T205434Z
LAST-MODIFIED:20220114T205434Z
UID:27796-1644334200-1644339600@scienceinboston.com
SUMMARY:Astellas Pharma Day
DESCRIPTION:Accelerate your biotech company\, startup\, or university’s innovation portfolio at our Astellas 2022 Pharma Day on February 8. \nMassBio’s Pharma Days® are unparalleled opportunities for emerging innovators to learn from and connect with world-leading biopharmaceutical companies. \nDiscover on February 8 | Join Astellas’ open information session on February 8 for the latest insights on its R&D strategy\, target therapeutic areas\, and partnering capabilities. This session will be followed by a networking reception. This session will feature: \n\nHide Goto\, Ph.D.\, President\, Astellas Institute for Regenerative Medicine\nMichael Luther\, Ph.D.\, MBA\, Head of Early Stage Partnering\, Astellas\nMichael Patane\, Ph.D.\, President\, Mitobridge\nMat Pletcher\, Ph.D.\, Division Head of Gene Therapy Research & Technical Operations\, Astellas Gene Therapies\nJoanna Stanicka\, Ph.D.\, CEO and Founder\, Axonis\n\nPlease note: MassBio is taking all appropriate precautions while also closely monitoring the latest public health guidance on COVID-19. Accordingly\, all attendees for this event are required to be fully vaccinated. \nConnect on February 8 | Innovators with small molecule\, gene therapy\, mRNA\, or cell therapy candidates or technology in the therapeutic areas listed below who are actively looking for licensing opportunities are encouraged to apply for a one-on-one meeting with Astellas representatives. Astellas’ target therapeutic areas are: \n•    Oncology\n•    Immuno-Science\n•    Mitochondria Biology\n•    Regeneration/Reprogramming\nApplications for one-on-one meetings can be found here\, and must be submitted by January 7\, 2022 at 12:00AM (midnight) ET. \nProtection of intellectual property rights (ex. patents\, trademarks\, copyright\, trade secrets\, etc.) of your concept is your responsibility and your responsibility alone. Information you include in your application will be shared with State of Possible partners. Please note that these partners did NOT sign Non-Disclosure Agreements (NDAs). Therefore\, you should not include any information in your application that you feel could be harmful to your company should that information be disclosed. \nPlease note that this will be a hybrid event\, with a limited number of in-person attendees. In-person attendance is available on a first-come-first-serve basis\, and all additional registrants will be placed on a waitlist. All attendees for this event are required to be fully vaccinated and masks will be required in all common areas of the event space\, except while eating or drinking.  
URL:https://scienceinboston.com/event/astellas-pharma-day-3/
LOCATION:MassBioHub & Online\, 700 Technology Square\, Cambridge\, MA\, 02139\, United States
END:VEVENT
END:VCALENDAR